CINGW · Cingulate Inc.

Cingulate Inc. reported its first quarter 2026 financial results, highlighting a strengthened balance sheet with cash and cash equivalents of $25.9 million as of March 31, 2026, up from $10.95 million at year-end 2025. The increase was primarily driven by a $12.0 million private placement in February 2026 and opportunistic use of at-the-market and stock purchase agreements. Working capital improved to $17.0 million from $1.7 million. The company's net loss widened to $9.3 million from $3.9 million in the prior year quarter, largely due to a significant increase in general and administrative expenses to $5.7 million (from $1.5 million) as Cingulate built out commercial infrastructure for the potential launch of CTx-1301, including increased headcount and costs related to the IQVIA sales force agreement. Research and development expenses decreased slightly to $2.2 million as clinical study activities concluded, partially offset by higher regulatory and manufacturing costs associated with the NDA review. Management believes the current cash position funds operations into 2027. The company continues to engage with the FDA on the CTx-1301 NDA, with a PDUFA target action date of May 31, 2026. Commercial readiness efforts are advancing across market access, distribution, omnichannel AI tools, and manufacturing scale-up. The CEO emphasized disciplined execution and positioning for a rapid launch upon potential FDA approval.